A Phase 3 interventional study of Ivacaftor and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 12 sites in 3 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 58th largest by enrollment, is one of 4 that started in 2012, is one of 45 in phase 3, and was the 16th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 4 started in 2012.
This study's enrollment of 39 is close to the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 55 (51%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 84th largest by enrollment of the 116 interventional ones that give a count, is one of 4 that started in 2012, is one of 62 in phase 3, and was the 18th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
Ivacaftor is the first CFTR modulator to show an improvement in CFTR function and clinical benefit in subjects with CF. Results from Phase 3 studies (VX08-770-102 [Study 102] [NCT00909532] and VX08-770-103 [Study 103] [NCT00909727]) showed that ivacaftor is effective in the treatment of subjects with CF who have the G551D-CFTR mutation, as evidenced by sustained improvements in CFTR channel function (measured by reduction in sweat chloride concentration) and corresponding substantial, durable improvements in lung function, pulmonary exacerbations, respiratory symptoms, and weight gain. Ivacaftor was also well tolerated, as evidenced by the rates and reasons for premature discontinuation and results of safety assessments.
Ivacaftor (Trade Name Kalydeco; 150 mg tablets) was initially approved in the United States for the treatment of CF in subjects 6 years of age and older who have a G551D mutation in the CFTR gene.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
Drug: Ivacaftor · Drug: Placebo
Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
Drug: Ivacaftor · Drug: Placebo
Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
Drug: Ivacaftor
150 mg tablet, oral use, administered twice a day (q12h)
Also known as: Kalydeco, VX-770
oral use, administered twice a day (q12h)
Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
Time frame: Part 1: Baseline (pre-dose Day 1), Week 8
Part 2: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through 24 Weeks of Treatment (Week 36 Visit)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Absolute change in percent predicted FEV1 over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2, as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
Time frame: Baseline (pre-dose Week 12), Week 36
Part 1: Change From Baseline in Body Mass Index (BMI) at Week 8
BMI was defined as weight in kilogram (kg) divided by height in meters\^2 (m\^2). Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
Time frame: Part 1: Baseline (pre-dose Day 1), Week 8
Part 2: Change From Baseline in Body Mass Index (BMI) at 24 Weeks of Treatment (Week 36 Visit)
BMI was defined as weight in kg divided by height in m\^2. Change in BMI over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
Time frame: Baseline (pre-dose Week 12), Week 36
Part 1: Change From Baseline in Sweat Chloride Through Week 8
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
Time frame: Part 1: Baseline (pre-dose Day 1), Week 8
Part 2: Change From Baseline in Sweat Chloride Through 24 Weeks of Treatment (Week 36 Visit)
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Change in sweat chloride over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
Time frame: Baseline (pre-dose Week 12), Week 36
Part 1: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
Time frame: Part 1: Baseline (pre-dose Day 1), Week 8
Part 2: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through 24 Weeks of Treatment (Week 36 Visit)
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Change in CFQ-R respiratory domain score over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
Time frame: Baseline (pre-dose Week 12), Week 36
Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.
Time frame: Part 1: From signing of informed consent up to Week 20
Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.
Time frame: Part 2: Week 20 up to Week 40
| Milestone | Part 1: Ivacaftor First, Then Placebo | Part 1: Placebo First, Then Ivacaftor | Part 2: Ivacaftor |
|---|---|---|---|
| Started | 20 | 19 | 0 |
| Completed | 18 | 18 | 0 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Need to extend washout period | 1 | 1 | 0 |
| Milestone | Part 1: Ivacaftor First, Then Placebo | Part 1: Placebo First, Then Ivacaftor | Part 2: Ivacaftor |
|---|---|---|---|
| Started | 18 | 18 | 0 |
| Completed | 18 | 18 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part 1: Ivacaftor First, Then Placebo | Part 1: Placebo First, Then Ivacaftor | Part 2: Ivacaftor |
|---|---|---|---|
| Started | 18 | 18 | 0 |
| Completed | 18 | 18 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part 1: Ivacaftor First, Then Placebo | Part 1: Placebo First, Then Ivacaftor | Part 2: Ivacaftor |
|---|---|---|---|
| Started | 0 | 0 | 36 |
| Completed | 0 | 0 | 36 |
| Not completed | 0 | 0 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
| percent predicted of FEV1 | Part 1: Ivacaftor | Part 1: Placebo |
|---|---|---|
| Baseline (n=38, 37) | 76.3659 ± 20.33450 | 79.3361 ± 20.83991 |
| Change Through Week 8 (n=37, 37) | 8.1308 ± 9.94676 | -5.8738 ± 7.23722 |
BMI was defined as weight in kilogram (kg) divided by height in meters\^2 (m\^2). Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
| kg/m^2 | Part 1: Ivacaftor | Part 1: Placebo |
|---|---|---|
| Baseline (n=38, 37) | 22.241 ± 5.1880 | 22.527 ± 4.9956 |
| Change at Week 8 (n=37, 37) | 0.748 ± 0.5793 | 0.043 ± 0.6980 |
BMI was defined as weight in kg divided by height in m\^2. Change in BMI over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
| kg/m^2 | Part 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor |
|---|---|
| Baseline | 22.222 ± 6.2919 |
| Change at Week 36 | 1.263 ± 0.7588 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
| millimole per liter (mmol/L) | Part 1: Ivacaftor | Part 1: Placebo |
|---|---|---|
| Baseline (n=38, 37) | 93.37 ± 18.099 | 94.23 ± 20.581 |
| Change Through Week 8 (n=36, 36) | -55.82 ± 24.890 | -5.63 ± 9.833 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Absolute change in percent predicted FEV1 over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2, as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
| percent predicted of FEV1 | Part 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor |
|---|---|
| Baseline | 74.8375 ± 19.36754 |
| Change Through Week 36 | 13.5307 ± 10.18174 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Change in sweat chloride over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
| mmol/L | Part 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor |
|---|---|
| Baseline (n=18) | 92.03 ± 11.468 |
| Change Through Week 36 (n=17) | -59.24 ± 32.566 |
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.
| units on a scale | Part 1: Ivacaftor | Part 1: Placebo |
|---|---|---|
| Baseline (n=38, 37) | 70.61 ± 17.409 | 74.55 ± 20.616 |
| Change Through Week 8 (n=37, 37) | 12.31 ± 16.891 | -2.33 ± 20.648 |
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Change in CFQ-R respiratory domain score over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.
| units on a scale | Part 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor |
|---|---|
| Baseline | 71.30 ± 19.526 |
| Change Through Week 36 | 11.42 ± 13.604 |
AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.
| participants | Part 1: Ivacaftor | Part 1: Placebo |
|---|---|---|
| AEs | 28 | 31 |
| SAEs | 4 | 7 |
AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.
| participants | Part 2: Ivacaftor |
|---|---|
| AEs | 30 |
| SAEs | 3 |
Collected over Part 1: From signing of informed consent up to Week 20; Part 2: Week 20 up to Week 40. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Ivacaftor | — | 4/38 (10.5%) | 27/38 (71.1%) |
| Part 1: Placebo | — | 7/37 (18.9%) | 30/37 (81.1%) |
| Part 2: Ivacaftor | — | 3/36 (8.3%) | 30/36 (83.3%) |
| Event | Part 1: Ivacaftor | Part 1: Placebo | Part 2: Ivacaftor |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/38 | 6/37 | 2/36 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/38 | 0/37 | 1/36 |
| DehydrationMetabolism and nutrition disorders | 0/38 | 0/37 | 1/36 |
| ConvulsionNervous system disorders | 0/38 | 0/37 | 1/36 |
| DizzinessNervous system disorders | 0/38 | 0/37 | 1/36 |
| Appendiceal MucocoeleGastrointestinal disorders | 0/38 | 1/37 | 0/36 |
| IntussusceptionGastrointestinal disorders | 0/38 | 1/37 | 0/36 |
| Paranasal CystRespiratory, thoracic and mediastinal disorders | 0/38 | 1/37 | 0/36 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/38 | 1/37 | 0/36 |
| Distal Ileal Obstruction SyndromeGastrointestinal disorders | 1/38 | 0/37 | 0/36 |
| Event | Part 1: Ivacaftor | Part 1: Placebo | Part 2: Ivacaftor |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 6/38 | 7/37 | 5/36 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 7/38 | 6/37 | 4/36 |
| HeadacheNervous system disorders | 3/38 | 5/37 | 4/36 |
| Abdominal painGastrointestinal disorders | 1/38 | 4/37 | 3/36 |
| NauseaGastrointestinal disorders | 1/38 | 4/37 | 1/36 |
| Upper respiratory tract infectionInfections and infestations | 1/38 | 2/37 | 3/36 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/38 | 3/37 | 3/36 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/38 | 1/37 | 3/36 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 3/38 | 3/37 | 2/36 |
| RalesRespiratory, thoracic and mediastinal disorders | 1/38 | 3/37 | 1/36 |
Full Analysis Set (FAS) was defined as all randomized subjects who received at least 1 dose of study drug (ivacaftor or placebo).
| Age, Continuous(years) | Part 1: Ivacaftor First, Then Placebo | Part 1: Placebo First, Then Ivacaftor | Total |
|---|---|---|---|
| Mean | 23.8 ± 13.25 | 21.7 ± 12.92 | 22.8 ± 12.96 |
| Sex: Female, Male(Participants) | Part 1: Ivacaftor First, Then Placebo | Part 1: Placebo First, Then Ivacaftor | Total |
|---|---|---|---|
| Female | 7 | 10 | 17 |
| Male | 13 | 9 | 22 |
The record gives a start of Jul 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →